Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Oakland, California and other locations
Dates
study started
study ends around

Description

Summary

The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.

Official Title

A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)

Details

The mitapivat group included 171 participants. The placebo group included 87 participants.

Keywords

Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia, Thalassemia, beta-Thalassemia, alpha-Thalassemia, Mitapivat

Eligibility

Locations

  • Children's Hospital Oakland
    Oakland California 94609-1809 United States
  • Stanford Medicine
    Palo Alto California 94304-1601 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Agios Pharmaceuticals, Inc.
ID
NCT04770779
Phase
Phase 3 research study
Study Type
Interventional
Participants
About 258 people participating
Last Updated